SCHEMBL3714000

SCHEMBL3714000

O=C(c1ccc(F)cc1)N1CCN(S(=O)(=O)c2ccc(Cl)cc2)CC1

nearest known ligand 0.76

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GPR183 P32249 1/20 0.65
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ HSP90AA1 P07900 1/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ LMNA P02545 1/20 0.62
▸ CA12 O43570 2/20 0.62
▸ CA1 P00915 2/20 0.62
▸ CA2 P00918 2/20 0.62
▸ CA7 P43166 2/20 0.62
▸ CA9 Q16790 2/20 0.62
▸ CA14 Q9ULX7 2/20 0.62
▸ PKM P14618 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10717731 0.86 CA12 (0.66) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL10674722 0.86 CA12 (0.66) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL7890110 0.86 LMNA (0.73) MEN1KMT2AL3MBTL1LMNACA12
Hydrochloric Acid SCHEMBL10719352 0.85 CA12 (0.64) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL1946614 0.85 L3MBTL1 (0.75) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL12761129 0.85 L3MBTL1 (0.75) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL7893660 0.85 USP2 (0.80) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL7077553 0.84 F10 (0.65) MEN1KMT2AL3MBTL1LMNACA12
SCHEMBL10717963 0.83 ALDH1A1 (0.67) GPR183MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL10670607 0.83 ALDH1A1 (0.67) GPR183MEN1KMT2AHSP90AA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010102663-A1 PIPERAZINE DERIVATIVES FOR USE IN THERAPY GLAXO GROUP LIMITED (GB) 2010-09-16 — — WO claimed
WO-2010102663-A1 PIPERAZINE DERIVATIVES FOR USE IN THERAPY GLAXO GROUP LIMITED (GB) 2010-09-16 — — WO disclosed
Send feedback